No Data
No Data
Express News | Artelo Biosciences Presents Data From Preclinical Studies On ART12.11 At 34th Annual International Cannabinoid Research Society Symposium
Artelo Biosciences Presents Comparative Data From Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people
Artelo Biosciences Announces Data Supporting Broad Potential Utility of Its FABP Inhibitor Platform
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE)
Express News | Artelo Biosciences Presents Preclinical Data On ART26.12 For Breast Cancer-Induced Bone Pain At 34th Annual International Cannabinoid Research Society Symposium
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium
SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tre
Maxim Group Maintains Artelo Biosciences(ARTL.US) With Buy Rating, Maintains Target Price $5
Maxim Group analyst Jason McCarthy maintains $Artelo Biosciences(ARTL.US)$ with a buy rating, and maintains the target price at $5.According to TipRanks data, the analyst has a success rate of 29.1% a
No Data